Polycythemia vera

Jun 17, 2020

Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera

May 07, 2020

Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

May 07, 2020

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

Oct 30, 2019

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera

Aug 16, 2019

FDA approves treatment for patients with rare bone marrow disorder

Jun 17, 2019

Data Presented At 24 Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients

Feb 21, 2019

PharmaEssentia and AOP Orphan Receive EU Approval of Besremi(TM) (Ropeginterferon Alfa-2b) for Treatment of Polycythemia Vera (PV) in EU

Dec 17, 2018

PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU

Dec 10, 2017

PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017

Jun 25, 2017

AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid